- Show all
- Abigail Coursolle
- Alejandra Pavisich
- Alejandra Pavisich
- Alexis Robles-Fradet
- Alicia Emanuel
- Amanda Avery
- Amy Chen
- Andy DiAntonio
- Arielle Linsey
- Brian Brooks
- Candace Gibson
- Carly Myers
- Cassandra LaRose
- Cat Duffy
- Catherine McKee
- Cathren Cohen
- Charlie Blodnieks
- Charly Gilfoil
- Christina Piecora
- Corey Davis
- Dania Douglas
- Daniel Young
- daryln
- David Machledt
- Deanna Hartog
- Elizabeth Edwards
- Elizabeth G. Taylor
- Emma Parker-Newton
- Eskedar Girmash
- Fabiola Carrión
- Georgesula Ziama
- Geron Gadd
- Hannah Eichner
- Hayley Penan
- Héctor Hernández-Delgado
- Ian McDonald
- Jane Perkins
- Jasmine Young
- Jennifer Lav
- Joe McLean
- Kally Xu
- Kasey Nichols
- Kimberly Lewis
- Leonardo Cuello
- lhigashi
- Lisa Munoz
- Liz McCaman Taylor
- Madeline Morcelle
- Mara Youdelman
- Margaret Okakpu
- Maya Levin
- Michelle Lilienfeld
- Michelle Yiu
- Miriam Delaney Heard
- Mizue Suito
- Priscilla Huang
- Rachel Holtzman
- Rolonda Donelson
- Sarah Grusin
- Sarah Somers
- Skyler Rosellini
- Susan Berke Fogel
- T. Nancy Lam
- veng
- Wayne Turner
- Zamir M. Brown
- Show all
- Alabama
- Alaska
- All United States
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District of Columbia
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- National
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
- April 3, 2023
National Health Law Program Comments on the DEA’s Proposed Rule on Telemedicine Prescribing of Controlled Medications
Read moreThe National Health Law Program (NHeLP) submitted comments on the Drug Enforcement Administration's (DEA) Notice of Proposed Rulemaking, "Telemedicine Prescribing of Controlled Substances When the Practitioner and the Patient Have Not Had a Prior In-Person Medical Evaluation." NHeLP believes that all people should have access to the health care…
- March 13, 2023
NHeLP Comments on the HHS Prior Authorization Proposed Rule (2023)
Read moreIn these comments on the Prior Authorization Proposed Rule, NHeLP urges HHS to go further to curb the abuse of prior authorization as a cost savings strategy that endangers patients’ health. NHeLP supports efforts to streamline prior authorization processing and bring greater transparency to denial rates and the clinical…
- March 7, 2023
National Health Law Program Comments on HHS’s Proposed Changes to Health Care Refusal Regulations
Read moreThe National Health Law Program submitted comments on the Department of Health and Human Services's (HHS) Notice of Proposed Rulemaking to implement federal health care refusal laws, called "Safeguarding the Rights of Conscience as Protected by Federal Statutes.” Our comments thank HHS for proposing to rescind the most harmful…
- November 1, 2022
Joint comment letter: Temporary Increase in Federal Medical Assistance Percentage (FMAP) in Response to the COVID–19 Public Health Emergency (PHE); Reopening of Public Comment Period
Read moreIn the last days of the Trump administration, the Centers for Medicare & Medicaid Services (CMS) finalized an Interim Final Rule (IFR) that creates exceptions to the Medicaid continuous coverage requirements in the Families First Coronavirus Response Act. The IFR allows states to reduce benefits and terminate eligibility in…
- October 11, 2022
Webinar: Gender-Affirming Care 101 for California Advocates
Read moreThis webinar provides an overview of the legal requirements on Medi-Cal and private health plans in California to provide gender-affirming care to Transgender, Gender Diverse, and Non-Binary Californians. Webinar Recording: Gender-Affirming Care 101 for California Advocates
- October 11, 2022
NHeLP Comments on Request for Information: Federal Evidence Agenda on LGBTQI+ Equity
Read moreNHeLP submitted comments to the White House Office of Science and Technology Policy in response to a request for information on LGBTQI+ demographic data collection. Our comments highlight the need for administrative data collection on LGBTQI+ populations in Medicaid, CHIP, Medicare, and the Health Care Marketplace.